Management of children exposed to multidrug-resistant Mycobacterium tuberculosis (Q37988983)

26 August 2017

title

Management of children exposed to multidrug-resistant Mycobacterium tuberculosis (English)

1 reference

Mycobacterium tuberculosis

26 August 2017

main subject

0 references

multiple drug resistance

1 reference

James A Seddon

1

0 references

Peter Godfrey-Faussett

series ordinal

2

object named as

Peter Godfrey-Faussett

1 reference

26 August 2017

5

Nulda Beyers

1 reference

26 August 2017

3

Anneke C Hesseling

1 reference

26 August 2017

4

Robert P Gie

1 reference

26 August 2017

6

H Simon Schaaf

1 reference

26 August 2017

publication date

27 February 2012

1 reference

Lancet Infectious Diseases

26 August 2017

published in

1 reference

26 August 2017

volume

12

1 reference

26 August 2017

issue

6

1 reference

26 August 2017

page(s)

469-479

1 reference

Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Update on the treatment of tuberculosis and latent tuberculosis infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Understanding latent tuberculosis: a moving target

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

1 reference

7 January 2021

Evaluation of young children in contact with adult multidrug-resistant pulmonary tuberculosis: a 30-month follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Highly discordant T cell responses in individuals with recent exposure to household tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

The utility of an interferon gamma release assay for diagnosis of latent tuberculosis infection and disease in children: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Interferon-gamma release assays and childhood tuberculosis: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

The prognosis of a positive tuberculin reaction in childhood and adolescence

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

A comparison of the virulence in Guinea-pigs of south indian and British tubercle bacilli

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Some observations on the pathogenicity of isoniazid-resistant variants of tubercle bacilli.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Risk of tuberculosis among contacts of isoniazid-resistant and isoniazid-susceptible cases

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

A recently evolved sublineage of the Mycobacterium tuberculosis Beijing strain family is associated with an increased ability to spread and cause disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Relationship between Mycobacterium tuberculosis genotype and the clinical phenotype of pulmonary and meningeal tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Risk factors for pediatric tuberculosis infection and disease after household exposure to adult index cases in Alaska

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Prevalence and risk factors for transmission of infection among children in household contact with adults having pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Clinical diagnosis of smear-negative pulmonary tuberculosis in low-income countries: the current evidence.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

The impact of human immunodeficiency virus type 1 on infectiousness of tuberculosis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

The infectiousness of tuberculosis patients coinfected with HIV

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Risk factors for tuberculosis infection in sub-Saharan Africa: a contact study in The Gambia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Risk Factors for Tuberculosis Infection in Children in Contact With Infectious Tuberculosis Cases in The Gambia, West Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

From exposure to disease: the role of environmental factors in susceptibility to and development of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Association between passive smoking and infection with Mycobacterium tuberculosis in children.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Tuberculosis transmission to young children in a South African community: modeling household and community infection risks

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Culture confirmed multidrug resistant tuberculosis: diagnostic delay, clinical features, and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Multidrug-resistant tuberculosis management in resource-limited settings

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

High incidence of tuberculosis among HIV-infected infants: evidence from a South African population-based study highlights the need for improved tuberculosis control strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Transmission of tuberculosis to close contacts of patients with multidrug-resistant tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Transmission of multidrug-resistant tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Epidemiology of pediatric tuberculosis using traditional and molecular techniques: Houston, Texas

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Primary drug-resistant tuberculosis in children. Correlation of drug-susceptibility patterns of matched patient and source case strains of Mycobacterium tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Community infection ratio as an indicator for tuberculosis control

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Reinfection and mixed infection cause changing Mycobacterium tuberculosis drug-resistance patterns

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Patients with active tuberculosis often have different strains in the same sputum specimen

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Treatment of latent infection with Mycobacterium tuberculosis: update 2010.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Childhood pulmonary tuberculosis: old wisdom and new challenges

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Twice weekly tuberculosis preventive therapy in HIV infection in Zambia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Reduced incidence of tuberculosis by prophylactic chemotherapy in subjects showing strong reactions to tuberculin testing

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Impact of tuberculosis preventive therapy on tuberculosis and mortality in HIV-infected children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Drugs for preventing tuberculosis in people at risk of multiple-drug-resistant pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Preventive therapy for contacts of multidrug-resistant tuberculosis. A Delphi survey

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Risk of tuberculosis in close contacts of patients with multidrug resistant tuberculosis: a nationwide cohort

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Management of pediatric multidrug-resistant tuberculosis and latent tuberculosis infections in New York City from 1995 to 2003.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Molecular action of anti-mycobacterial agents

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Clinical pharmacology and therapeutic drug monitoring in neonates and children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: implications for international pediatric dosing guidelines.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Low levels of pyrazinamide and ethambutol in children with tuberculosis and impact of age, nutritional status, and human immunodeficiency virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Clinical pharmacokinetics of the antituberculosis drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Isoniazid pharmacokinetics in children according to acetylator phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

A multicentre study of the early bactericidal activity of anti-tuberculosis drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Isoniazid preventive therapy and risk for resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Severe or fatal liver injury in 50 patients in the United States taking rifampin and pyrazinamide for latent tuberculosis infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Good tolerance of pyrazinamide in children with pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Tolerance of pyrazinamide in short course chemotherapy for pulmonary tuberculosis in children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Quinolone arthropathy in animals versus children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Fluoroquinolones, tuberculosis, and resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Comparison of the bactericidal activity of various fluoroquinolones against Mycobacterium tuberculosis in an in vitro experimental model

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Minimal inhibitory concentration of isoniazid in isoniazid-resistant Mycobacterium tuberculosis isolates from children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Genome and MIC stability in Mycobacterium tuberculosis and indications for continuation of use of isoniazid in multidrug-resistant tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Failure of chemoprophylaxis with standard antituberculosis agents in child contacts of multidrug-resistant tuberculosis cases.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

The diarylquinoline TMC207 for multidrug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Chemoprophylaxis of multidrug-resistant tuberculous infection in HIV-uninfected individuals using ciprofloxacin and pyrazinamide. A decision analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Predictors of failure to complete treatment for latent tuberculosis infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

A tuberculin screening and isoniazid preventive therapy program in an inner-city population

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Adherence to isoniazid preventive chemotherapy: a prospective community based study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Pharmacology of second-line antituberculosis drugs and potential for interactions with antiretroviral agents

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

When should children with HIV infection be started on antiretroviral therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Early Antiretroviral Therapy and Mortality among HIV-Infected Infants

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Pediatric HIV immune reconstitution inflammatory syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Cost-effectiveness of treating multidrug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Feasibility and cost-effectiveness of treating multidrug-resistant tuberculosis: a cohort study in the Philippines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Scaling up programmatic management of drug-resistant tuberculosis: a prioritized research agenda

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

Proportion of tuberculosis transmission that takes place in households in a high-incidence area

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970366-8

7 January 2021

10.1016/S1473-3099(11)70366-8

Identifiers

DOI

1 reference

26 August 2017

1 reference